CVS Health Corporation (CVS)
CVS Health Post-Q4 Earnings: Is the Stock Worth Buying Now?
CVS Health's adjusted EPS outlook for 2025 reflects expectations of a meaningful recovery in Medicare Advantage and continued growth in Health Services.
Why CVS Stock Thrashed the Market on Thursday
For the second day in a row, CVS Health's (CVS 4.98%) stock price saw a satisfying jump on Thursday. It closed the day almost 5% higher, on the back of both lingering optimism and news of another in a series of analyst price target raises.
CVS Health Gains Momentum After Q4 Performance, Analyst Upgrades Stock
On Wednesday, CVS Health Corp CVS reported fourth-quarter sales of $97.71 billion, beating the consensus of $97.19 billion.
CVS shares are up 45% this year — here's why it may be starting to turn its business around
CVS Health could be starting to turn itself around after a dismal 2024. Its shares are up more than 45% this year, outperforming pharmacy rival Walgreens and other insurers like UnitedHealth Group and Cigna.
CVS wins upgrade to buy as analyst sees more upside potential than its peers
A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits businesses.
CVS Health: Earnings Beat Ignites Stock Rally
Shares of CVS Health Corporation NYSE: CVS experienced a jolt, rising over 15% on February 12, 2025, as the market responded to the release of its fourth-quarter 2024 earnings report. CVS Health's stock price increase comes after a period of decline, causing investors to question whether this is a temporary upswing or a sign of a genuine turnaround.
These Analysts Boost Their Forecasts On CVS Health Following Upbeat Earnings
CVS Health Corp CVS reported upbeat earnings for its fourth quarter on Wednesday.
CVS Health Jumps On Q4 Earnings Beat, But Downgrading To Hold
Despite a >10% rise in CVS Health's stock price from my initial BUY recommendation, CVS Health is downgraded to Hold due to substantial political risks and declining cash flow. CVS faces significant challenges, including DOJ lawsuits, potential business separation, political scrutiny, and declining cash flow, impacting its turnaround prospects. CVS reported strong Q4 sales and new leadership from the new CEO David Joyner may bode well for shareholders.
S&P 500 Gains and Losses Today: CVS Stock Jumps as Pharmacy Segment Delivers Growth
Major U.S. equities indexes were mixed on Wednesday as the latest Consumer Price Index (CPI) data showed an unexpected uptick in inflation during January.
CVS CEO defends pharmacy middlemen, accuses drugmakers of 'monopolistic' practices
CVS Health CEO David Joyner defended controversial pharmacy middlemen, who are widely accused of inflating prescription medication prices, and instead accused manufacturers of "monopolistic" practices that keep drug costs high in the U.S. Joyner, who stepped into the role in October, spent much of his opening remarks on the company's fourth-quarter earnings call discussing so-called pharmacy benefit managers, or PBMs.
CVS shares move higher on upbeat Q4 report
CVS Health Corp (NYSE:CVS)'s shares surged more than 15% after the pharmacy chain posted positive financial results for the fourth quarter. Adjusted earnings per share of $1.19 on revenue of $97.71 billion topped analyst expectations of EPS of $0.91 on revenue of $96.89 billion.
Why CVS Health Stock Popped Today
Shares of CVS Health (CVS 13.66%) were soaring Wednesday after the diversified healthcare giant's fourth-quarter results topped estimates and management offered better-than-expected guidance for 2025.
